iBio (IBIO)
Developing AI-enabled antibodies for obesity and body composition.
$1.32
Pre-market0.00 (0.00%)
At close$1.32(+4.76%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions52 holders · as of Mar 31, 2026 | 39.11% | 19.43M shares | |
| Insiders7 holders · as of Mar 27, 2026 | 0.61% | 304.9K shares | |
| Otherremainder | 60.28% | 29.95M shares |
49.68M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (49.68M in the company's Sep 3, 2026 report, 15.79M elsewhere); stakes use the report.
Institutions13F, as of Mar 31, 2026
52 holders · 19.43M shares · 16 new positions · 32 increased · 8 reduced · 13 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Affinity Asset Advisors, LLC | 3.11M | 6.25% | +1.05M | May 14, 2026 |
| Frazier Life Sciences Management, L.P. | 1.95M | 3.93% | 0 | May 15, 2026 |
| Ecor1 Capital, LLC | 1.58M | 3.19% | −645.0K | May 15, 2026 |
| Millennium Management LLC | 1.55M | 3.12% | +1.55Mnew | May 15, 2026 |
| Logos Global Management LP | 1.30M | 2.62% | −700.0K | May 15, 2026 |
| Vanguard Capital Management LLC | 1.09M | 2.19% | +1.09Mnew | May 15, 2026 |
| Balyasny Asset Management L.P. | 1.01M | 2.03% | −85.2K | May 15, 2026 |
| Ikarian Capital, LLC | 957.1K | 1.93% | 0 | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Cormorant Asset Management, LP | 9.99% | 3.83M | 13G | May 15, 2026 ↗ |
| Affinity Asset Advisors, LLC | 9.99% | 3.49M | 13G | May 14, 2026 ↗ |
| SilverArc Capital Management, LLC | 9.99% | 2.18M | 13G | Nov 14, 2025 ↗ |
| Adage Capital Management, L.P. | 9.99% | 2.18M | 13G | Nov 13, 2025 ↗ |
| Affinity Healthcare Fund, LP | 9.99% | 4.28M | 13G | Aug 26, 2025 ↗ |
| Sirenia Capital Management LP | 9.90% | 11.59M | 13G | May 15, 2026 ↗ |
| Vestal Point Capital, LP | 9.90% | 4.28M | 13G | Nov 14, 2025 ↗ |
| Opaleye Management, Inc. | 7.60% | 750.0K | 13G | Feb 14, 2025 ↗ |
| Ikarian Capital, LLCincl. Neil Shahrestani | 6.60% | 599.9K | 13G | Nov 14, 2024 ↗ |
| Frazier Life Sciences Public Fund, L.P. | 5.70% | 1.95M | 13G | May 12, 2026 ↗ |
| Lynx1 Capital Management LP | 5.40% | 2.81M | 13G | Aug 14, 2026 ↗ |
| Integrated Core Strategies (US) LLC | 5.20% | 1.23M | 13G | Jan 22, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Mar 26, 2026 | Marc Banjakofficer: Chief Legal Officer | Purchase · 2 lots | 13,934 | $1.65 | 25,000 |
| Mar 19, 2026 | Martin Brennerdirector, officer: See Remarks | Purchase | 12,336 | $2.02 | 30,652 |
| Mar 19, 2026 | Felipe Duranofficer: Chief Financial Officer | Purchase | 24,835 | $2.02 | 35,974 |
CongressHouse and Senate disclosures
Not reported.